ALZN

Alzamend Neuro, Inc. (ALZN) - Q2 2025 Filing Summary

Business Context and Reporting Period

This Form 10-Q covers the quarterly period ended October 31, 2025. Alzamend Neuro, Inc. is a clinical-stage biopharmaceutical company developing novel treatments for Alzheimer's disease, bipolar disorder, major depressive disorder, and PTSD. The company has no product revenue and relies on equity and debt financing to fund operations. The filing identifies the company as a smaller reporting company and an emerging growth company.

Key Financial Metrics

Material Changes vs. Prior Period

• Operating Expenses: For the three months ended October 31, 2025, total operating expenses decreased by 27% to $998,109 compared to $1,358,068 in the prior year period. This was driven by a 43% decrease in R&D expenses and a 22% decrease in G&A expenses.
• Year-to-Date Expenses: For the six months ended October 31, 2025, total operating expenses increased by 59% to $3.7 million compared to $2.3 million in the prior year. This increase was primarily due to a 270% surge in R&D expenses (from $518k to $1.9M) related to the timing of the Phase IIA brain imaging study with Massachusetts General Hospital.
• Capital Structure: The company completed the conversion of all outstanding Series B and Series C Convertible Preferred Stock into Common Stock during the period. Additionally, the company raised $4.0 million in net proceeds from the issuance of Series C Convertible Preferred Stock.
• Share Count: Weighted average common shares outstanding increased significantly due to reverse stock splits (1-for-10 in July 2024 and 1-for-9 in May 2025) and preferred stock conversions.

Outlook, Risks, and Management Commentary

• Liquidity and Going Concern: Management has expressed substantial doubt about the company's ability to continue as a going concern. With cash of $4.4 million and a burn rate resulting in a $3.7 million net loss for the six-month period, the company states it will need to raise additional capital to fund operations for the next 12 months. Failure to secure funding could force delays in clinical trials.
• Clinical Progress:
  • AL001: The company completed the clinical portion of the Phase II study in healthy human subjects in November 2025 and expects to report topline data in Q1 2026. Nonclinical studies showed AL001 achieves higher brain lithium concentrations with lower plasma levels compared to lithium carbonate.
  • ALZN002: The company terminated its contract with the previous CRO (Biorasi) in February 2024 and is pursuing a replacement to continue the Phase I/IIA clinical trial.
• Internal Controls: The company disclosed a material weakness in internal control over financial reporting due to insufficient resources in the accounting department, affecting the review of manual journal entries and account reconciliations. Remediation efforts are ongoing.
• Subsequent Events: On November 13, 2025, the Board approved a new 2025 Stock Incentive Plan and granted 1.59 million options to directors and officers, subject to stockholder approval.

Investor Verification Checklist

• Cash Runway: Verify the sufficiency of the $4.4 million cash balance against the current burn rate and the timeline for the next capital raise.
• ALZN002 CRO Status: Confirm the engagement of a new Contract Research Organization (CRO) to resume the ALZN002 clinical trial.
• AL001 Data Release: Monitor the Q1 2026 topline data release for the Phase II healthy subject study.
• Internal Control Remediation: Review future filings for updates on the remediation of the material weakness in financial reporting controls.
• Dilution Risk: Assess the impact of the recently approved 1.59 million option grants and potential future equity issuances on shareholder dilution.